Title: Edotreotide
CAS Registry Number: 204318-14-9
CAS Name: N-[[4,7,10-Tris(carboxymethyl)-1,4,7,10-tetraazacyclododec-1-yl]acetyl]-D-phenylalanyl-L-cysteinyl-L-tyrosyl-D-tryptophyl-L-lysyl-L-threonyl-N-[(1R,2R)-2-hydroxy-1-(hydroxymethyl)propyl]-L-cysteinamide cyclic(2®7)-disulfide
Additional Names: (DOTA D-Phe1,Tyr3)octreotide; DOTATOC
Manufacturers' Codes: SMT-487
Molecular Formula: C65H92N14O18S2
Molecular Weight: 1421.64
Percent Composition: C 54.92%, H 6.52%, N 13.79%, O 20.26%, S 4.51%
Literature References: Octapeptide analog of somatostatin, q.v. Designed for targeted radiotherapy vs somatostatin receptor-expressing tumors. Prepn: R. Albert et al., EP 714911; eidem, US 6183721 (1996, 2001 both to Novartis); idem, et al., Bioorg. Med. Chem. Lett. 8, 1207 (1998). Solution-phase synthesis: M. Schottelius et al., Tetrahedron Lett. 44, 2393 (2003). In vivo antineoplastic activity: B. Stolz et al., Eur. J. Nucl. Med. 25, 668 (1998). Receptor binding study: J. C. Reubi et al., ibid. 27, 273 (2000). Clinical pharmacokinetics: F. Jamar et al., Eur. J. Nucl. Med. Mol. Imaging 30, 510 (2003). Clinical evaluation in neuroendocrine tumors: C. Waldherr et al., J. Nucl. Med. 43, 610 (2002).
Properties: Prepd as acetate. [a]22D -14.75° (c = 0.52 in 95% acetic acid).
Optical Rotation: [a]22D -14.75° (c = 0.52 in 95% acetic acid)
Derivative Type: 90Y chelate
CAS Registry Number: 322407-70-5
Manufacturers' Codes: 90Y-SMT-487
Trademarks: OctreoTher (Novartis)
Therap-Cat: 90Y chelate as antineoplastic.
Keywords: Somatostatin Analog.
Edoxudine Edrecolomab Edrophonium Chloride EDTA EEDQ

CAS number 204318-14-9 N
PubChem 158782
Jmol-3D images Image 1
Molecular formula C65H92N14O18S2
Molar mass 1,421.64 g mol−1
 N (verify) (what is: YesY/N?)
Except where noted otherwise, data are given for materials in their standard state (at 25 °C (77 °F), 100 kPa)
Infobox references
90Y labelled edotreotide

Edotreotide (USAN, codenamed SMT487, also known as (DOTA0-Phe1-Tyr3)octreotide, or DOTATOC) is a substance which, when bound to various radionuclides, is used in the treatment and diagnosis of certain types of cancer.[1]

It has been the subject of a trial by the National Cancer Institute to determine its effects in young cancer patients (up to 25 years of age) for its ability to locate malignant cancer cells without harming normal cells. Specific cancers being included in the trial include neuroblastoma, childhood brain tumours and gastrointestinal cancer.[2]